Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
about
Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndromeUpdate on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current EvidenceNon-vitamin K antagonist oral anticoagulants and antiphospholipid syndromeDirect oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced ageDirect Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation.Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.Management of non-vitamin K antagonist oral anticoagulants in the perioperative settingApproach to the new oral anticoagulants in family practice: part 1: comparing the options.A Novel Direct Factor Xa Inhibitory Peptide with Anti-Platelet Aggregation Activity from Agkistrodon acutus Venom HydrolysatesSubtle renal dysfunction and bleeding risk in atrial fibrillation: symmetric dimethylarginine predicts HAS-BLED scoreNovel oral anticoagulants: clinical pharmacology, indications and practical considerations.The pharmacology of novel oral anticoagulants.Direct oral anticoagulants as alternative treatment options for the effective long-term treatment of patients with pulmonary embolism in primary care: a review.New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.The inflammatory actions of coagulant and fibrinolytic proteases in disease.Dosing of Target-Specific Oral Anticoagulants in Special Populations.Drug-drug interactions of non-vitamin K oral anticoagulants.Direct oral anticoagulant considerations in solid organ transplantation: A review.Drug metabolism and liver disease: a drug-gene-environment interaction.Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know.Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis.Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis.Apixaban-induced liver injury.Quantitative Correlation of Conformational Binding Enthalpy with Substrate Specificity of Serine Proteases.A case of rivaroxaban associated intracranial hemorrhageAppropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment.The Coagulant Factor Xa Induces Protease-Activated Receptor-1 and Annexin A2-Dependent Airway Smooth Muscle Cytokine Production and Cell Proliferation.Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines.Comparison between the impact of morning and evening doses of rivaroxaban on the circadian endogenous coagulation rhythm in healthy subjects.Spontaneous intracranial epidural hematoma during rivaroxaban treatment.Portal vein thrombosis in patients with cirrhosis: underdiagnosis and undertreatment?Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis.
P2860
Q24185813-284DA1BD-F133-44E2-9F9D-48383F44DDA5Q26782483-B7A72E74-ABAF-48D5-BCF5-1B89CE3A1F49Q28067420-DB2EAEFC-C62D-4BFB-8750-DB16CC7DD03AQ28079930-16773F5C-5DDA-4311-82C9-032562A92BE7Q30277819-147A1794-7F06-4087-8579-61BDA72081B2Q33854667-5CE00622-B387-470A-A85B-E29EFB2EE258Q34207558-A94B6A53-9196-427B-B420-556F4460F02FQ34497581-8786121B-A904-48CB-9DA1-77E215AFD54CQ35672783-F3A2761F-2A6C-4138-8198-3758F9600B82Q35962795-B1F3C625-4DE7-4B8B-979F-43D1B487B4F9Q38101845-5F1E909D-ACE7-4E99-B52A-5DE729716C64Q38122099-04C74992-CB24-4279-9CEB-B91B70F1815CQ38216837-B29CA39B-12B7-4DEF-859B-045CA42EF2D8Q38221642-89288975-710A-4489-90B1-8FBAD73DF300Q38423064-E3320225-4107-4468-BF86-050D656830F0Q38535649-FE84EE28-7303-4A0A-8532-48A945A7B1C8Q38830358-84256BC6-F8C1-4117-BD4C-803A04D842FCQ39012313-0DC6A0DC-8A0F-403D-9604-1BD52C0CF7CFQ39037269-22B52A57-45D4-45E9-A294-5E9AE4D41CBBQ39041243-A77F6033-D5F9-4BA3-88D5-BEC177FA983AQ39251865-950ECF83-5B0E-465F-B594-DB78E8EECB58Q39453858-A334362E-204C-4F93-B4FF-DB34AE9E3267Q40410373-007BF4DD-3022-4309-AFAC-B5737D10A9FCQ40533024-5F1557A4-D54F-4D6C-B82F-92884C000937Q41818888-624E0618-DFA0-4A00-8A7B-4880C1DEBC39Q42050160-22A94264-EBD5-4BDA-A3BE-2DB29E0BBF98Q48152210-5A8C031B-326A-4BE6-8AB8-9CCB7BA26065Q48165386-055E571A-0D11-415D-981D-15B18098F055Q48248862-573CF52F-7D70-48E3-AAAC-44B384118B08Q50953346-B910A0BE-0DB8-4D04-A052-1B7683979FECQ52957805-4F25C001-E47A-476B-BD3C-00B05D1484BAQ53783646-BFD7CAB2-0AD1-46D4-BC5F-F915399D1E87Q55442446-57AB7B10-5A4E-46EC-A4DA-ECF7801AD054
P2860
Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Anticoagulant therapy with the ...... ients with hepatic impairment.
@en
type
label
Anticoagulant therapy with the ...... ients with hepatic impairment.
@en
prefLabel
Anticoagulant therapy with the ...... ients with hepatic impairment.
@en
P2860
P1476
Anticoagulant therapy with the ...... ients with hepatic impairment.
@en
P2093
Jochen Graff
Sebastian Harder
P2860
P2888
P304
P356
10.1007/S40262-013-0034-0
P577
2013-04-01T00:00:00Z
P6179
1009586817